Intervention, Prognosis and Mechanism of Covid-19 Infection in Patients With Underlying Diseases
Launched by THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY · Jul 27, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how Covid-19 affects people with certain health issues, like chronic liver disease, cancer, autoimmune diseases, and even healthy individuals. The researchers want to understand how Covid-19 impacts these vulnerable groups, what makes some people more likely to get very sick from the virus, and how the infection might affect their existing health conditions. To do this, they will collect information on participants, including their age, gender, health history, and vaccination status.
If you or a loved one has one of the underlying conditions mentioned and tests positive for Covid-19, you might be eligible to participate in this study. Participants will be asked to sign a consent form and provide details about their health. The study is not yet recruiting, so there’s no immediate need to apply, but it will help researchers learn more about how to protect and care for vulnerable populations during the pandemic.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Sign the informed consent form before enrollment, and be able to complete the research according to the requirements of the research protocol.
- • 2. Enrolled patients need to have basic diseases, including chronic liver disease, chronic kidney disease, chronic lung disease, solid tumors, AIDS, rheumatic immune diseases, diabetes, etc.
- • 3. When entering the group, patients with new crowns need to be confirmed by evidence of a positive test for new coronavirus nucleic acid (CT value \<35) or a positive test for new coronavirus antigen.
- Exclusion Criteria:
- • 1. Participate in clinical trials of other investigational drugs or medical devices within 3 months before screening, and take experimental drugs or use medical devices.
- • 2. Positive pregnancy test during lactation or screening period.
- • 3. Subjects who, in the investigator's opinion, have other factors that are not suitable for participating in this study.
About The Second Affiliated Hospital Of Chongqing Medical University
The Second Affiliated Hospital of Chongqing Medical University is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. As a prominent academic hospital in China, it combines cutting-edge medical technology with a strong emphasis on education and training for healthcare professionals. The hospital is committed to conducting high-quality, ethically sound clinical research that contributes to the development of new therapies and enhances healthcare outcomes. With a multidisciplinary team of experts, the Second Affiliated Hospital fosters collaboration and strives to address critical health challenges through rigorous scientific investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Peng Hu, PhD.
Study Director
The Second Affiliated Hospital of Chongqing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported